BWS Financial Inc

BWS provides independent stock specific research focused on companies with distinct value that are going through a special situation where there is a tangible catalyst not priced in. The catalyst can be anything from new product, restructuring, M&A, management change, change in business strategy, etc. BWS’s focus is to understand the change and evaluate the potential return for investors.

BWS utilizes a self formed proprietary approach in discovering stocks by putting great emphasis on deep research. BWS does generate short recommendations following a similar criteria.

Independent Stock Specific Research

PLXP: Band Back Together, Initiating with Buy

Founder, BWS Financial Inc

Hamed Khorsand

Founder

Equity Bottom-Up

<ul type="disc"><li>There is new medical opinion on the daily use of aspirin to prevent first heart attack or stroke affirming why there is market opportunity for VAZALORE even though the monthly price is greater than other aspirin options on the market. When we initiated coverage of PLx Pharma (PLXP) we had highlighted the growing concerns within the medical community of the risks associated with taking aspirin daily.</li></ul> <ul type="disc"><li>The U.S. Preventive Services Task Force said the health risks for patients 60 years old and older outweigh the benefits for taking a daily dose of aspirin. This is not the first-time daily aspirin regimen has come under scrutiny.</li></ul> <ul type="disc"><li>VAZALORE works by breaking up in the duodenum instead of the stomach. This is different than traditional aspirin and has shown clinical evidence of improved results.</li></ul> <ul type="disc"><li>We are emboldened by the medical community reaffirmation on traditional aspirin risks being a positive for VAZALORE and PLXP’s stock price. We would recommend owning shares of PLXP prior to the earnings release.</li></ul>

There is new medical opinion on the daily use of aspirin to prevent first heart attack or stroke affirming why there is market opportunity for VAZALORE even though the monthly price is greater than other aspirin options on the market. When we initiated coverage of PLx Pharma (PLXP) we had highlighted the growing concerns within the medical community of the risks associated with taking aspirin daily. The U.S. Preventive Services Task Force said the health risks for patients 60 years old and older outweigh the benefits for taking a daily dose of aspirin. This is not the first-time daily aspirin regimen has come under scrutiny. VAZALORE works by breaking up in the duodenum instead of the stomach. This is different than traditional aspirin and has shown clinical evidence of improved results. We are emboldened by the medical community reaffirmation on traditional aspirin risks being a positive for VAZALORE and PLXP’s stock price. We would recommend owning shares of PLXP prior to the earnings release.

PLx Pharma

PLXP: Headlines to Buy